*The treatment process includes leukapheresis, manufacturing, administration, and adverse event monitoring. A single dose of ABECMA contains a cell suspension of 300 to 510 x 106 CAR-positive T cells in 1 or more infusion bags.
ABECMA is a one-time infusion* created just for you
ABECMA, a CAR T cell therapy, uses cells from your body's immune system to fight multiple myeloma. ABECMA uses T cells that have been reprogrammed to find and destroy specific target cells, which may include cancer cells and normal cells.
One type of immune cell is the T cell, which helps to fight off harmful diseases that can make you sick. T cells do this by using hooks on their surfaces called receptors, as explained in the diagram below.
How ABECMA is made
YOUR T CELLS
T cells are a type of immune cell that help the body fight off diseases, including cancer
CARs
CARs are “hooks” (receptors) that
are added to
your
ABECMA
Your newly made CAR T cells that are powered to find and fight multiple myeloma cells
ABECMA cells are created by adding new hooks, called chimeric antigen receptors (CARs), to your existing T cells. This makes them better able to attach to multiple myeloma cells and destroy them. ABECMA can also target normal, healthy cells.
Here’s how ABECMA works
Inside your body, ABECMA CAR T cells look for a protein found on multiple myeloma cells called a B-cell maturation antigen, or BCMA. It may be found on some healthy cells, too. Once found, your ABECMA CAR T cells attach to the multiple myeloma cells and destroy them.